Ontology highlight
ABSTRACT: Significance
Sorafenib therapy for HCC may impact HCV replication and viral gene expression. In HCV-positive patients accrued to CLAGB 80802 phase III study evaluating the addition of doxorubicin to sorafenib, HCV titer levels were evaluated at baseline and different timepoints. Sorafenib did not impact HCV titer levels. Despite an improved PFS in patients with detectable higher level HCV titers at baseline, no difference in OS was noted.
SUBMITTER: Abou-Alfa GK
PROVIDER: S-EPMC10919207 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
Abou-Alfa Ghassan K GK Geyer Susan M SM Nixon Andrew B AB Innocenti Federico F Shi Qian Q Kumthekar Priya P Jacobson Sawyer S El Dika Imane I Yaqubie Amin A Lopez Juan J Huang Binhui B Tang Yi-Wei YW Wen Yujia Y Schwartz Lawrence H LH El-Khoueiry Anthony B AB Knox Jennifer J JJ Rajdev Lakshmi L Bertagnolli Monica M MM Meyerhardt Jeffrey A JA O'Reilly Eileen M EM Venook Alan P AP
Cancer research communications 20240301 3
Sorafenib blocks nonstructural protein 5A (NS5A)-recruited c-Raf-mediated hepatitis C virus (HCV) replication and gene expression. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via sorafenib putatively differ in the presence or absence of doxorubicin. Cancer and Leukemia Group B (CALGB) 80802 (Alliance) randomized phase III trial of doxorubicin plus sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC), showed no improvement in median overall survival (OS). W ...[more]